Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
CMB International: Maintains INNOVENT BIO's "Buy" rating, with the Target Price raised to 57.67 HKD.
CMB International has released a research report stating that it maintains a "Buy" rating for INNOVENT BIO (01801), being bullish on the global potential of INNOVENT's Innovative Drugs pipeline, and has raised the target price to HKD 57.67 (previous value: HKD 55.21; WACC: 9.5%, perpetual growth rate: 3.5%). The company has licensed the global rights of the new DLL3ADC (IBI3009) to Roche, receiving an upfront payment of USD 80 million and up to USD 1 billion in milestone payments and sales sharing. The drug is expected to receive IND approval for global Phase 1 research in December 2024. Regarding the DLL3 target, besides
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
Here's Why Novartis (NVS) Is a Strong Growth Stock
Top Gap Ups and Downs on Monday: AR, DJT, MSTR and More
Novartis Reports Positive Results for Intrathecal Zolgensma
NoobGirl : bro is this real that roaring kitty gonna come?